Copyright © 2005, European Society of Cardiology
Chemokines induce matrix metalloproteinase-2 through activation of epidermal growth factor receptor in arterial smooth muscle cells
aZena and Michael A.Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, N. Y., 10029 USA
bDepartment of Immunobiology, Mount Sinai School of Medicine, New York, N. Y., 10029 USA
cDivision of Liver Diseases, Mount Sinai School of Medicine, New York, N. Y., 10029 USA
dSamuel L. Bronfman Department of Medicine, Mount Sinai School of Medicine, New York, N. Y., 10029 USA
* Corresponding author. Box 1030, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA. Tel.: +1 212 241 8299; fax: +1 212 860 7032. Email address: alison.schecter{at}mssm.edu
Objective: Matrix metalloproteinases (MMP) are critical to smooth muscle cell (SMC) migration in vivo. MMP-2 dysregulation has been implicated in the pathogenesis of abnormal arterial remodeling, aneurysm formation, and atherosclerotic plaque structure and stability. The chemokine receptors CCR3 and CXCR4 are present and functional on SMC and are up-regulated in vascular diseases such as atherosclerosis. We sought to determine a potential mechanism for chemokine receptor-mediated effects on the vasculature by asking whether the chemokines eotaxin (CCL11), the ligand for CCR3, and stromal cell-derived cell factor (SDF-1, CXCL12), the ligand for CXCR4, induce MMP-2 in SMC. Studies were then performed to define the signaling pathways involved.
Methods and results: As determined by RT-PCR, Western blotting and zymography, SDF-1 and eotaxin induce MMP-2 mRNA, protein, and activity in SMC. An anti-CCR3 antibody and a CXCR4 antagonist blocked proMMP-2 induction by SDF-1 and eotaxin, the respective ligands for the chemokine receptors CXCR4 and CCR3, suggesting that the inductions by these chemokines are receptor-mediated. Receptor cross-talk between G-protein-coupled receptors (GPCR) and the epidermal growth factor receptor (EGFR) is a method of expanding the GPCRs' signaling repertoire. We demonstrate, for the first time to our knowledge, that in SMC, chemokine induction of proMMP-2 is dependent on activation of the EGFR. Interestingly, by blocking the ligand binding domain of EGFR, we demonstrate that activation of EGFR by SDF-1 and eotaxin occurs through different cellular pathways.
Conclusion: The pro-inflammatory chemokines eotaxin and SDF induce proMMP-2 activation of EGFR through two different pathways. SDF and eotaxin, as regulators of proMMP-2 expression and by engaging in receptor cross-talk, may play critical roles in atherosclerosis, restenosis, and plaque rupture. These ligands and their respective receptors, CXCR4 and CCR3, therefore may serve as future potential therapeutic targets.
KEYWORDS Atherosclerosis; Cytokines; Matrix metalloproteinases
1 Both authors contributed equally to the manuscript.
Time for primary review 31 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. E. White, T. C.C. Tan, A. E. John, C. Whatling, W. L. McPheat, and D. R. Greaves Fractalkine has anti-apoptotic and proliferative effects on human vascular smooth muscle cells via epidermal growth factor receptor signalling Cardiovasc Res, November 12, 2009; (2009) cvp341v2. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Gilmore, R. M. Gonterman, K. Menon, G. Lorch, D. J. Riese II, A. Robling, and J. Foley Reconstitution of Amphiregulin-Epidermal Growth Factor Receptor Signaling in Lung Squamous Cell Carcinomas Activates PTHrP Gene Expression and Contributes to Cancer-Mediated Diseases of the Bone Mol. Cancer Res., October 1, 2009; 7(10): 1714 - 1728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Tilley, I.-M. Kim, P. A. Patel, J. D. Violin, and H. A. Rockman {beta}-Arrestin Mediates {beta}1-Adrenergic Receptor-Epidermal Growth Factor Receptor Interaction and Downstream Signaling J. Biol. Chem., July 24, 2009; 284(30): 20375 - 20386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Levina, B. M. Nolen, A. M. Marrangoni, P. Cheng, J. R. Marks, M. J. Szczepanski, M. E. Szajnik, E. Gorelik, and A. E. Lokshin Role of Eotaxin-1 Signaling in Ovarian Cancer Clin. Cancer Res., April 15, 2009; 15(8): 2647 - 2656. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Braunersreuther, S. Steffens, C. Arnaud, G. Pelli, F. Burger, A. Proudfoot, and F. Mach A Novel RANTES Antagonist Prevents Progression of Established Atherosclerotic Lesions in Mice Arterioscler Thromb Vasc Biol, June 1, 2008; 28(6): 1090 - 1096. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Zemani, J.-S. Silvestre, F. Fauvel-Lafeve, A. Bruel, J. Vilar, I. Bieche, I. Laurendeau, I. Galy-Fauroux, A. M. Fischer, and C. Boisson-Vidal Ex Vivo Priming of Endothelial Progenitor Cells With SDF-1 Before Transplantation Could Increase Their Proangiogenic Potential Arterioscler Thromb Vasc Biol, April 1, 2008; 28(4): 644 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Prasad, Z. Qamri, J. Wu, and R. K. Ganju Slit-2/Robo-1 modulates the CXCL12/CXCR4-induced chemotaxis of T cells J. Leukoc. Biol., September 1, 2007; 82(3): 465 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Bosse, K. Maghni, and T. J. Hudson 1{alpha},25-Dihydroxy-vitamin D3 stimulation of bronchial smooth muscle cells induces autocrine, contractility, and remodeling processes Physiol Genomics, April 24, 2007; 29(2): 161 - 168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Martinson, M. P. Hans, G.-D. David, and A. M. Elizabeth Readers' choice: Hot papers downloaded in 2006 Cardiovasc Res, March 1, 2007; 73(4): 619 - 622. [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Greenlee, Z. Werb, and F. Kheradmand Matrix Metalloproteinases in Lung: Multiple, Multifarious, and Multifaceted Physiol Rev, January 1, 2007; 87(1): 69 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Newby, M. Pauschinger, and F. G. Spinale From tadpole tails to transgenic mice: Metalloproteinases have brought about a metamorphosis in our understanding of cardiovascular disease Cardiovasc Res, February 15, 2006; 69(3): 559 - 561. [Full Text] [PDF]
|
|